In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach.
COVID-19
SARS-CoV-2
antiretrovirals
drug repurposing
molecular docking
Journal
AIMS microbiology
ISSN: 2471-1888
Titre abrégé: AIMS Microbiol
Pays: United States
ID NLM: 101697141
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
09
2022
revised:
26
11
2022
accepted:
13
12
2022
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
10
3
2023
Statut:
epublish
Résumé
Drug repurposing is a valuable strategy for rapidly developing drugs for treating COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against SARS-CoV-2 in vitro and in silico. The cytotoxicity of lamivudine, emtricitabine, tenofovir, abacavir, efavirenz and raltegravir on Vero E6 was evaluated by MTT assay. The antiviral activity of each of these compounds was evaluated via a pre-post treatment strategy. The reduction in the viral titer was assessed by plaque assay. In addition, the affinities of the antiretroviral interaction with viral targets RdRp (RNA-dependent RNA polymerase), ExoN-NSP10 (exoribonuclease and its cofactor, the non-structural protein 10) complex and 3CLpro (3-chymotrypsin-like cysteine protease) were evaluated by molecular docking. Lamivudine exhibited antiviral activity against SARS-CoV-2 at 200 µM (58.3%) and 100 µM (66.7%), while emtricitabine showed anti-SARS-CoV-2 activity at 100 µM (59.6%), 50 µM (43.4%) and 25 µM (33.3%). Raltegravir inhibited SARS-CoV-2 at 25, 12.5 and 6.3 µM (43.3%, 39.9% and 38.2%, respectively). The interaction between the antiretrovirals and SARS-CoV-2 RdRp, ExoN-NSP10 and 3CLpro yielded favorable binding energies (from -4.9 kcal/mol to -7.7 kcal/mol) using bioinformatics methods. Lamivudine, emtricitabine and raltegravir showed in vitro antiviral effects against the D614G strain of SARS-CoV-2. Raltegravir was the compound with the greatest in vitro antiviral potential at low concentrations, and it showed the highest binding affinities with crucial SARS-CoV-2 proteins during the viral replication cycle. However, further studies on the therapeutic utility of raltegravir in patients with COVID-19 are required.
Sections du résumé
Background
UNASSIGNED
Drug repurposing is a valuable strategy for rapidly developing drugs for treating COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against SARS-CoV-2 in vitro and in silico.
Methods
UNASSIGNED
The cytotoxicity of lamivudine, emtricitabine, tenofovir, abacavir, efavirenz and raltegravir on Vero E6 was evaluated by MTT assay. The antiviral activity of each of these compounds was evaluated via a pre-post treatment strategy. The reduction in the viral titer was assessed by plaque assay. In addition, the affinities of the antiretroviral interaction with viral targets RdRp (RNA-dependent RNA polymerase), ExoN-NSP10 (exoribonuclease and its cofactor, the non-structural protein 10) complex and 3CLpro (3-chymotrypsin-like cysteine protease) were evaluated by molecular docking.
Results
UNASSIGNED
Lamivudine exhibited antiviral activity against SARS-CoV-2 at 200 µM (58.3%) and 100 µM (66.7%), while emtricitabine showed anti-SARS-CoV-2 activity at 100 µM (59.6%), 50 µM (43.4%) and 25 µM (33.3%). Raltegravir inhibited SARS-CoV-2 at 25, 12.5 and 6.3 µM (43.3%, 39.9% and 38.2%, respectively). The interaction between the antiretrovirals and SARS-CoV-2 RdRp, ExoN-NSP10 and 3CLpro yielded favorable binding energies (from -4.9 kcal/mol to -7.7 kcal/mol) using bioinformatics methods.
Conclusion
UNASSIGNED
Lamivudine, emtricitabine and raltegravir showed in vitro antiviral effects against the D614G strain of SARS-CoV-2. Raltegravir was the compound with the greatest in vitro antiviral potential at low concentrations, and it showed the highest binding affinities with crucial SARS-CoV-2 proteins during the viral replication cycle. However, further studies on the therapeutic utility of raltegravir in patients with COVID-19 are required.
Identifiants
pubmed: 36891537
doi: 10.3934/microbiol.2023002
pii: microbiol-09-01-002
pmc: PMC9988408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20-40Informations de copyright
© 2023 the Author(s), licensee AIMS Press.
Déclaration de conflit d'intérêts
Conflicts of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study was supported by Universidad de Antioquia (strategy # UdeA responde al COVID-19), CODI (Act 2020–36850) and Universidad Cooperativa de Colombia. BPIN 2020000100131-SGR.
Références
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
J Biomol Struct Dyn. 2022 Mar;40(5):2010-2023
pubmed: 33084512
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):
pubmed: 35165203
Presse Med. 1995 Jan 14;24(2):103-10
pubmed: 7899342
Curr Med Chem. 2006;13(25):2995-3003
pubmed: 17073642
J Clin Pharmacol. 2021 May;61(5):581-590
pubmed: 33217030
Nucleic Acids Res. 2021 May 21;49(9):5382-5392
pubmed: 33956156
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Nat Rev Microbiol. 2021 Nov;19(11):685-700
pubmed: 34535791
iScience. 2021 Nov 19;24(11):103341
pubmed: 34723159
Cells. 2021 Apr 06;10(4):
pubmed: 33917481
J Infect Dis. 1974 Jan;129(1):82-5
pubmed: 4358268
Intensive Care Med. 2021 Aug;47(8):867-886
pubmed: 34251506
Antivir Chem Chemother. 2006;17(5):285-9
pubmed: 17176633
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618761299
pubmed: 29534608
Nucleic Acids Res. 2019 Jul 2;47(W1):W345-W349
pubmed: 31114880
Commun Biol. 2022 Feb 22;5(1):154
pubmed: 35194144
Nucleic Acids Res. 2022 Feb 22;50(3):1484-1500
pubmed: 35037045
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Front Immunol. 2022 May 02;13:879036
pubmed: 35585980
Interdiscip Sci Rev. 2015 Jul 3;40(3):308-328
pubmed: 26740732
Am J Gastroenterol. 2002 Jul;97(7):1618-28
pubmed: 12135009
Biomedica. 2020 Oct 30;40(Supl. 2):148-158
pubmed: 33152198
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487867
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31481446
J Proteome Res. 2020 Nov 6;19(11):4690-4697
pubmed: 32692185
Front Pharmacol. 2020 Aug 26;11:1224
pubmed: 32982720
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Acta Pharmacol Sin. 2020 Sep;41(9):1167-1177
pubmed: 32737471
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):665-76
pubmed: 22509856
J Infect Public Health. 2020 Dec;13(12):1856-1861
pubmed: 33168456
Microorganisms. 2021 Apr 03;9(4):
pubmed: 33916747
RSC Adv. 2020 Jul 17;10(45):26792-26803
pubmed: 35515752
J Biomol Struct Dyn. 2021 Aug;39(13):4633-4646
pubmed: 32573355
J Biomol Struct Dyn. 2021 Sep;39(14):4949-4961
pubmed: 32579059
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Front Microbiol. 2022 Mar 18;13:721103
pubmed: 35369500
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27381-27387
pubmed: 33051297
Inform Med Unlocked. 2020;19:100345
pubmed: 32395606
Future Med Chem. 2009 Nov;1(8):1429-52
pubmed: 21426058
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
Biomed Pharmacother. 2021 Jun;138:111544
pubmed: 34311539
J Biomol Struct Dyn. 2022 Oct;40(16):7367-7380
pubmed: 33734021
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
Acta Pharm. 2021 Aug 30;72(1):1-8
pubmed: 36651526
Front Oncol. 2021 Jul 21;11:664794
pubmed: 34367956
Int J Biol Macromol. 2021 Jan 31;168:272-278
pubmed: 33309661
Antimicrob Agents Chemother. 2004 Apr;48(4):1073-81
pubmed: 15047504
Molecules. 2021 Nov 16;26(22):
pubmed: 34833991
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127377
pubmed: 32738988
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:90-98
pubmed: 33521390
Science. 2020 May 15;368(6492):779-782
pubmed: 32277040
EClinicalMedicine. 2022 Jan;43:101242
pubmed: 34957385
J Biomol Struct Dyn. 2021 May;39(8):2679-2692
pubmed: 32266873
PLoS Pathog. 2013 Aug;9(8):e1003565
pubmed: 23966862
Antimicrob Agents Chemother. 2011 Feb;55(2):879-87
pubmed: 21078936
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33766889
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
Heliyon. 2020 Aug 11;6(8):e04642
pubmed: 32802982
Comput Struct Biotechnol J. 2020 Mar 30;18:784-790
pubmed: 32280433
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
EClinicalMedicine. 2021 Aug;38:100993
pubmed: 34222849
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161
pubmed: 22474613
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32105-32113
pubmed: 33239446
Curr Opin Virol. 2019 Apr;35:57-62
pubmed: 31125806
Front Pharmacol. 2018 Sep 24;9:1089
pubmed: 30319422
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9436-41
pubmed: 26159422
Biochem Pharmacol. 2020 Oct;180:114169
pubmed: 32710969
PLoS One. 2016 Nov 30;11(11):e0166318
pubmed: 27902714
J Infect Public Health. 2020 Sep;13(9):1210-1223
pubmed: 32561274
Nucleic Acids Res. 2020 Jul 2;48(W1):W48-W53
pubmed: 32297936
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451